|
Series
|
Country
|
Period
|
AUS/FLUS Rate %
|
LLE Malignancy Rate %
|
ULE Malignancy Rate %
|
|---|
|
Present Study
|
Canada
|
2014–19
|
18.1 (205/1130)
|
13.2 (24/182)
|
25.3% (24/95)
|
|
The Bethesda System [11]
|
N/A
|
2009
|
≤7
|
~ 5–15
|
N/A
|
|
The Bethesda System [18]
|
N/A
|
2017
|
≤10
|
~ 10–30
|
N/A
|
|
Bernstein et al. [19]
|
Canada
|
2010–13
|
12.0
|
37 (86/233)
|
46 (86/187)
|
|
Erivwo & Ghosh [20]
|
Canada
|
2010–13
|
5.5
|
29.8 (54/181)
|
N/A
|
|
Oosthuizen et al. [21]
|
Canada
|
2010–16
|
N/A
|
N/A
|
32 (30/93)
|
|
Williams et al. [22]
|
Canada
|
2006–10
|
18.8
|
N/A
|
24.7 (N/A)
|
|
Wu et al. [15]
|
United States
|
2006–08
|
27.2
|
N/A
|
6 (3/51)
|
|
Hong et al. [16]
|
South Korea
|
2011–14
|
N/A
|
10.2 (70/687)
|
72.9 (70/96)
|
|
Ho et al. [23]
|
United States
|
2008–11
|
8.0
|
26.6 (144/541)
|
37.8 (144/381)
|
|
Cavalheiro et al. [26]
|
Brazil
|
2010–14
|
N/A
|
N/A
|
15.7 (75/478)
|
|
Mileva et al. [27]
|
Republic of Macedonia
|
2012–16
|
5.9
|
N/A
|
31.2 (35/112)a
|
|
Al-Abbadi et al. [28]
|
Saudi-Arabia
|
2010–14
|
4.4
|
N/A
|
29 (12/42)a
|
|
Wong et al. [29]
|
United States
|
2008–12
|
9
|
N/A
|
33.1 (60/181)
|
|
Yaprak Bayrak et al. [30]
|
Turkey
|
2012–17
|
4.2
|
N/A
|
25.0 (27/108)
|
|
Sullivan et al. [31]
|
United States
|
2003–12
|
6
|
17 (56/332)
|
33 (56/168)
|
|
Topaloglu et al. [32]
|
Turkey
|
N/A
|
N/A
|
N/A
|
23.4 (105/449)
|
|
Vanderlaan et al. [33]
|
United States
|
2005–09
|
10.9
|
29.0 (96/331)a
|
48.2 (96/199)
|
- Abbreviations: AUS/FLUS atypia of undetermined significance/follicular lesion of undetermined significance, LLE lower limit estimate, ULE upper limit estimate
- aIncludes malignant/benign diagnosis based on histopathology, core needle biopsy, or rFNA
